{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:53:27Z","timestamp":1765475607635,"version":"3.48.0"},"reference-count":36,"publisher":"Innovative Healthcare Institute","issue":"1","license":[{"start":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T00:00:00Z","timestamp":1670803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,1]]},"abstract":"ABSTRACT<\/jats:title>\n \n Introduction<\/jats:title>\n This study aims to assess safety and effectiveness of pertuzumab in combination with trastuzumab and docetaxel in the neoadjuvant treatment (NeoT) of HER2-positive breast cancer.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Two consecutive retrospective cohorts (n = 94, 2012\u20132015 and 2015\u20132017) of adult women with HER2-positive breast cancer, receiving NeoT at the breast clinic in Portugal (IPO-Porto), were followed. All patients had surgery and received trastuzumab as adjuvant therapy. The 2012\u20132015 cohort received doxorubicin, cyclophosphamide, docetaxel plus trastuzumab, whereas the 2015\u20132017 cohort was treated with the same protocol plus pertuzumab.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The 2012\u20132015 cohort was older (median 53 years), with locally advanced tumors (48.1%), mostly hormone receptor positive (59.3%). The 2015\u20132017 cohort was younger (median 43 years) with 60% operable tumors. Pathologic complete response (pCR) improved in the second cohort, while maintaining a good safety profile and tolerability. Clinical staging (p = 0.001) and hormone receptor (p = 0.003) were significant predictors of pCR, but not treatment regimen (p = 0.304).<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Further research with larger samples and longer follow-up is needed to understand the clinical differences. Clinical effectiveness of treatment should also be measured through overall and progression-free survival.<\/jats:p>\n <\/jats:sec>","DOI":"10.36401\/jipo-22-12","type":"journal-article","created":{"date-parts":[[2022,12,12]],"date-time":"2022-12-12T15:58:58Z","timestamp":1670860738000},"page":"1-9","source":"Crossref","is-referenced-by-count":3,"title":["Pertuzumab in Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment for HER2-Positive Breast Cancer"],"prefix":"10.36401","volume":"6","author":[{"given":"Cla\u0301udia","family":"Vieira","sequence":"first","affiliation":[{"name":"1 Medical Oncology Department, Instituto Portugue\u0302s de Oncologia do Porto, Porto, Portugal"},{"name":"4 Molecular Oncology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal"},{"name":"5 Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"Andreia","family":"Borges","sequence":"additional","affiliation":[{"name":"2 Outcomes Research Lab\u2014IPO Porto, Instituto Portugue\u0302s de Oncologia do Porto, Porto, Portugal"},{"name":"3 Management, Outcomes Research, and Economics in Healthcare Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal"}]},{"given":"Filipa F.","family":"Pereira","sequence":"additional","affiliation":[{"name":"1 Medical Oncology Department, Instituto Portugue\u0302s de Oncologia do Porto, Porto, Portugal"}]},{"given":"Pedro","family":"Antunes","sequence":"additional","affiliation":[{"name":"6 Surgical Oncology Department, Instituto Portugue\u0302s de Oncologia do Porto, Porto, Portugal"}]},{"given":"Patri\u0301cia","family":"Redondo","sequence":"additional","affiliation":[{"name":"2 Outcomes Research Lab\u2014IPO Porto, Instituto Portugue\u0302s de Oncologia do Porto, Porto, Portugal"},{"name":"3 Management, Outcomes Research, and Economics in Healthcare Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal"}]},{"given":"Lui\u0301s","family":"Antunes","sequence":"additional","affiliation":[{"name":"7 Cancer Epidemiology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal"},{"name":"8 Department of Epidemiology, Instituto Portugue\u0302s de Oncologia do Porto, Porto, Portugal"}]},{"given":"Jose\u0301 M.","family":"Lopes","sequence":"additional","affiliation":[{"name":"1 Medical Oncology Department, Instituto Portugue\u0302s de Oncologia do Porto, Porto, Portugal"}]},{"given":"Francisco R.","family":"Gonc\u0327alves","sequence":"additional","affiliation":[{"name":"10 MEDCIDS\/Faculty of Medicine, University of Porto, Porto, Portugal"}]},{"given":"Marina","family":"Borges","sequence":"additional","affiliation":[{"name":"2 Outcomes Research Lab\u2014IPO Porto, Instituto Portugue\u0302s de Oncologia do Porto, Porto, Portugal"},{"name":"3 Management, Outcomes Research, and Economics in Healthcare Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal"}]},{"given":"Maria J.","family":"Bento","sequence":"additional","affiliation":[{"name":"7 Cancer Epidemiology Group, IPO Porto Research Center (CI-IPOP), Portuguese Oncology Institute of Porto (IPO Porto), Porto, Portugal"},{"name":"9 Department of Population Studies, Institute of Biomedical Sciences Abel Salazar, University of Porto, Porto, Portugal"}]}],"member":"22027","published-online":{"date-parts":[[2022,12,13]]},"reference":[{"key":"2023013016571388300_i2590-017X-6-1-1-b01","unstructured":"Cancer Today. gco.iarc.fr. Accessed Mar 2, 2022.\n \n gco.iarc.fr\/today"},{"key":"2023013016571388300_i2590-017X-6-1-1-b02","unstructured":"Portugal Source: Globocan 2020.\n The Global Cancer Observatory. Published March 2021. Accessed Mar 4, 2022.\n \n gco.iarc.fr\/today\/data\/factsheets\/populations\/620-portugal-fact-sheets.pdf"},{"key":"2023013016571388300_i2590-017X-6-1-1-b03","doi-asserted-by":"crossref","unstructured":"Cardoso\n F,\n \n \n Senkus\n E,\n \n \n Costa\n A,\n \n et al.\n \n 4th ESO\u2013ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4).\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2018;\n\t\t\t\t\t29:\n\t\t\t\t\t1634\u2013\n\t\t\t\t\t1657.","DOI":"10.1093\/annonc\/mdy192"},{"key":"2023013016571388300_i2590-017X-6-1-1-b04","doi-asserted-by":"crossref","unstructured":"Iqbal\n N,\n \n \n Iqbal\n N.\n \n \n Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications.\n\t\t\t\t\tMol Biol Int.\n\t\t\t\t\t2014;\n\t\t\t\t\t2014:\n\t\t\t\t\t1\u2013\n\t\t\t\t\t9.","DOI":"10.1155\/2014\/852748"},{"key":"2023013016571388300_i2590-017X-6-1-1-b05","unstructured":"Agus\n DB,\n \n \n Akita\n RW,\n \n \n Fox\n WD,\n \n et al.\n \n A potential role for activated HER-2 in prostate cancer.\n\t\t\t\t\tSemin Oncol.\n\t\t\t\t\t2000;\n\t\t\t\t\t27(6 suppl 11):\n\t\t\t\t\t76\u2013\n\t\t\t\t\t83;\n\t\t\t\t\tdiscussion,92\u2013\n\t\t\t\t\t100."},{"key":"2023013016571388300_i2590-017X-6-1-1-b06","doi-asserted-by":"crossref","unstructured":"Moasser\n MM,\n \n \n Krop\n IE.\n \n \n The evolving landscape of HER2 targeting in breast cancer.\n\t\t\t\t\tJAMA Oncol.\n\t\t\t\t\t2015;\n\t\t\t\t\t1:\n\t\t\t\t\t1154.","DOI":"10.1001\/jamaoncol.2015.2286"},{"key":"2023013016571388300_i2590-017X-6-1-1-b07","doi-asserted-by":"crossref","unstructured":"Mota\n JM,\n \n \n Collier\n KA,\n \n \n Barros Costa\n RL,\n \n et al.\n \n A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer.\n\t\t\t\t\tOncotarget.\n\t\t\t\t\t2017;\n\t\t\t\t\t8:\n\t\t\t\t\t89284\u2013\n\t\t\t\t\t89306.","DOI":"10.18632\/oncotarget.18467"},{"key":"2023013016571388300_i2590-017X-6-1-1-b08","doi-asserted-by":"crossref","unstructured":"Wee\n P,\n \n \n Wang\n Z.\n \n \n Epidermal growth factor receptor cell proliferation signaling pathways.\n\t\t\t\t\tCancers (Basel).\n\t\t\t\t\t2017;\n\t\t\t\t\t9:\n\t\t\t\t\t52.","DOI":"10.3390\/cancers9050052"},{"key":"2023013016571388300_i2590-017X-6-1-1-b09","unstructured":"Hoffmann\n FLRL.\n \n \n Application for the addition of Perjeta \u00ae (Pertuzumab) on the WHO Model List of Essential Medicines. 2018. Accessed Mar 4, 2022.\n \n www.who.int\/selection_medicines\/committees\/expert\/22\/applications\/s8.2_pertuzumab.pdf"},{"key":"2023013016571388300_i2590-017X-6-1-1-b10","unstructured":"The National Center for Pharmacoeconomics.\n Cost-effectiveness of Pertuzumab (Perjeta) (in combination of trastuzumab and chemotherapy) for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. Published May 2016. Accessed Mar 10, 2022.\n \n www.ncpe.ie\/wp-content\/uploads\/2015\/09\/Summary-Pertuzumab-16.pdf"},{"key":"2023013016571388300_i2590-017X-6-1-1-b11","unstructured":"NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company. nice.org.uk. Published Feb 15,\n 2019.\n\t\t\t\t\tAccessed Mar 2, 2022.www.nice.org.uk\/news\/article\/nice-draft-guidance-recommends-pertuzumab-for-new-breast-cancer-indication-after-improved-price-offer-from-company"},{"key":"2023013016571388300_i2590-017X-6-1-1-b12","doi-asserted-by":"crossref","unstructured":"Schneeweiss\n A,\n \n \n Chia\n S,\n \n \n Hickish\n T,\n \n et al.\n \n Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2013;\n\t\t\t\t\t24:\n\t\t\t\t\t2278\u2013\n\t\t\t\t\t2284.","DOI":"10.1093\/annonc\/mdt182"},{"key":"2023013016571388300_i2590-017X-6-1-1-b13","doi-asserted-by":"crossref","unstructured":"Squires\n H,\n \n \n Pandor\n A,\n \n \n Thokala\n P,\n \n et al.\n \n Pertuzumab for the neoadjuvant treatment of early-stage HER2-positive breast cancer: an evidence review group perspective of a NICE single technology appraisal.\n\t\t\t\t\tPharmacoeconomics.\n\t\t\t\t\t2018;\n\t\t\t\t\t36:\n\t\t\t\t\t29\u2013\n\t\t\t\t\t38.","DOI":"10.1007\/s40273-017-0556-7"},{"key":"2023013016571388300_i2590-017X-6-1-1-b14","doi-asserted-by":"crossref","unstructured":"Gianni\n L,\n \n \n Pienkowski\n T,\n \n \n Im\n YH,\n \n et al.\n \n Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2012;\n\t\t\t\t\t13:\n\t\t\t\t\t25\u2013\n\t\t\t\t\t32.","DOI":"10.1016\/S1470-2045(11)70336-9"},{"key":"2023013016571388300_i2590-017X-6-1-1-b15","unstructured":"Perjeta: Annex I Summary of Product Characteristics. Accessed Mar 2,\n 2022.\n\t\t\t\t\twww.ema.europa.eu\/en\/documents\/product-information\/perjeta-epar-product-information_en.pdf"},{"key":"2023013016571388300_i2590-017X-6-1-1-b16","unstructured":"Prescott\n C,\n \n \n Richardson\n J,\n \n \n Joshi\n B,\n \n et al.\n \n Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer.\n \n nice.org.uk. Published 2016. Accessed Mar 10, 2022. www.nice.org.uk\/guidance\/ta424\/resources\/pertuzumab-for-the-neoadjuvant-treatment-of-her2positive-breast-cancer-pdf-82604663691973"},{"key":"2023013016571388300_i2590-017X-6-1-1-b17","unstructured":"Kenny\n L,\n \n \n Donegan\n E,\n \n \n Feist\n T.\n \n \n Pertuzumab for adjuvant treatment of early HER2-positive breast cancer. Accessed Mar 2,\n 2022.\n\t\t\t\t\tnice.org.uk."},{"key":"2023013016571388300_i2590-017X-6-1-1-b18","doi-asserted-by":"crossref","unstructured":"Cardoso\n F,\n \n \n Costa\n A,\n \n \n Senkus\n E,\n \n et al.\n \n 3rd ESO\u2013ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).\n\t\t\t\t\tBreast.\n\t\t\t\t\t2017;\n\t\t\t\t\t31:\n\t\t\t\t\t244\u2013\n\t\t\t\t\t259.","DOI":"10.1016\/j.breast.2016.10.001"},{"key":"2023013016571388300_i2590-017X-6-1-1-b19","doi-asserted-by":"crossref","unstructured":"Gradishar\n WJ,\n \n \n Anderson\n BO,\n \n \n Balassanian\n R,\n \n et al.\n \n NCCN Guidelines Insights: Breast Cancer, Version 1.2017.\n\t\t\t\t\tJ Natl Compr Canc Netw.\n\t\t\t\t\t2017;\n\t\t\t\t\t15:\n\t\t\t\t\t433\u2013\n\t\t\t\t\t451.","DOI":"10.6004\/jnccn.2017.0044"},{"key":"2023013016571388300_i2590-017X-6-1-1-b20","unstructured":"Breast Cancer Invasive.\n \n www.nccn.org\/patients. Published 2020. Accessed Mar 2, 2022. www.nccn.org\/patients\/guidelines\/content\/PDF\/breast-invasive-patient.pdf"},{"key":"2023013016571388300_i2590-017X-6-1-1-b21","doi-asserted-by":"crossref","unstructured":"Dieci\n MV,\n \n \n Vernaci\n G,\n \n \n Guarneri\n V.\n \n \n Escalation and de-escalation in HER2 positive early breast cancer.\n\t\t\t\t\tCurr Opin Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t31:\n\t\t\t\t\t35\u2013\n\t\t\t\t\t42.","DOI":"10.1097\/CCO.0000000000000492"},{"key":"2023013016571388300_i2590-017X-6-1-1-b22","doi-asserted-by":"crossref","unstructured":"Piccart\n M,\n \n \n Procter\n M,\n \n \n Fumagalli\n D,\n \n et al.\n \n Interim overall survival analysis of APHINITY (BIG 4-11): a randomized multicenter, double-blind, placebo-controlled trial comparing chemotherapy plus trastuzumab plus pertuzumab versus chemotherapy plus trastuzumab plus placebo as adjuvant therapy in patients with operable HER2-positive early breast cancer.\n\t\t\t\t\tIn:General Session Abstracts.\n\t\t\t\t\tAmerican Association for Cancer Research;2020.\n\t\t\t\t\tAbstract GS1-04.","DOI":"10.1158\/1538-7445.SABCS19-GS1-04"},{"key":"2023013016571388300_i2590-017X-6-1-1-b23","doi-asserted-by":"crossref","unstructured":"Borges\n A,\n \n \n Pereira\n F,\n \n \n Redondo\n P,\n \n et al.\n \n The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data.\n\t\t\t\t\tHealth Econ Rev.\n\t\t\t\t\t2021;\n\t\t\t\t\t11:\n\t\t\t\t\t33.","DOI":"10.1186\/s13561-021-00332-0"},{"key":"2023013016571388300_i2590-017X-6-1-1-b24","unstructured":"Bento\n MJ,\n Laranja Pontes,\n\t\t\t\t\t\tGonc\u0327alvesAF,et al.\n \n Registo Oncolo\u0301gico 2017. Instituto Portugue\u0302s de Oncologia do Porto; 2017."},{"key":"2023013016571388300_i2590-017X-6-1-1-b25","doi-asserted-by":"crossref","unstructured":"Cardoso\n F,\n \n \n Kyriakides\n S,\n \n \n Ohno\n S,\n \n et al.\n \n Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.\n\t\t\t\t\tAnn Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t30:\n\t\t\t\t\t1194\u2013\n\t\t\t\t\t1220.","DOI":"10.1093\/annonc\/mdz173"},{"key":"2023013016571388300_i2590-017X-6-1-1-b26","doi-asserted-by":"crossref","unstructured":"Attard\n CL,\n \n \n Pepper\n AN,\n \n \n Brown\n ST,\n \n et al.\n \n Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.\n\t\t\t\t\tJ Med Econ.\n\t\t\t\t\t2015;\n\t\t\t\t\t18:\n\t\t\t\t\t173\u2013\n\t\t\t\t\t188.","DOI":"10.3111\/13696998.2014.979938"},{"key":"2023013016571388300_i2590-017X-6-1-1-b27","doi-asserted-by":"crossref","unstructured":"Gianni\n L,\n \n \n Pienkowski\n T,\n \n \n Im\n YH,\n \n et al.\n \n 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.\n\t\t\t\t\tLancet Oncol.\n\t\t\t\t\t2016;\n\t\t\t\t\t17:\n\t\t\t\t\t791\u2013\n\t\t\t\t\t800.","DOI":"10.1016\/S1470-2045(16)00163-7"},{"key":"2023013016571388300_i2590-017X-6-1-1-b28","doi-asserted-by":"crossref","unstructured":"Hamy-Petit\n AS,\n \n \n Belin\n L,\n \n \n Bonsang-Kitzis\n H,\n \n et al.\n \n Pathological complete response and prognosis after neoadjuvant chemotherapy for HER2-positive breast cancers before and after trastuzumab era: results from a real-life cohort.\n\t\t\t\t\tBr J Cancer.\n\t\t\t\t\t2016;\n\t\t\t\t\t114:\n\t\t\t\t\t44\u2013\n\t\t\t\t\t52.","DOI":"10.1038\/bjc.2015.426"},{"key":"2023013016571388300_i2590-017X-6-1-1-b29","doi-asserted-by":"crossref","unstructured":"Pennisi\n A,\n \n \n Kieber-Emmons\n T,\n \n \n Makhoul\n I,\n \n \n Hutchins\n L.\n \n \n Relevance of pathological complete response after neoadjuvant therapy for breast cancer. Breast Cancer (Auckl).\n 2016;\n\t\t\t\t\t10:BCBCR.S33163.","DOI":"10.4137\/BCBCR.S33163"},{"key":"2023013016571388300_i2590-017X-6-1-1-b30","doi-asserted-by":"crossref","unstructured":"Silva\n LCFF,\n \n \n de Arruda\n LSM,\n \n \n David\n WJ,\n \n et al.\n \n Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer. Einstein (Sa\u0303o Paulo).\n 2019;\n\t\t\t\t\t17.DOI: 10.31744\/einstein_journal\/2019AO3434","DOI":"10.31744\/einstein_journal\/2019AO3434"},{"key":"2023013016571388300_i2590-017X-6-1-1-b31","doi-asserted-by":"crossref","unstructured":"Von Minckwitz\n G,\n \n \n Huang\n CS,\n \n \n Mano\n MS,\n \n et al.\n \n Trastuzumab emtansine for residual invasive HER2-positive breast cancer.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2019;\n\t\t\t\t\t380:\n\t\t\t\t\t617\u2013\n\t\t\t\t\t628.","DOI":"10.1056\/NEJMoa1814017"},{"key":"2023013016571388300_i2590-017X-6-1-1-b32","doi-asserted-by":"crossref","unstructured":"Hurvitz\n SA,\n \n \n Martin\n M,\n \n \n Jung\n KH,\n \n et al.\n \n Neoadjuvant trastuzumab emtansine and pertuzumab in human epidermal growth factor receptor 2\u2013positive breast cancer: three-year outcomes from the phase III KRISTINE Study.\n\t\t\t\t\tJ Clinl Oncol.\n\t\t\t\t\t2019;\n\t\t\t\t\t37:\n\t\t\t\t\t2206\u2013\n\t\t\t\t\t2216.","DOI":"10.1200\/JCO.19.00882"},{"key":"2023013016571388300_i2590-017X-6-1-1-b33","unstructured":"Stenger\n M.\n \n \n 2019 ASCO: 3-year outcomes in the KRISTINE trial on neoadjuvant trastuzumab emtansine plus pertuzumab in HER2-positive breast cancer. ascopost.com. Published 2019. Accessed Mar 2, 2022.\n \n ascopost.com\/News\/60158"},{"key":"2023013016571388300_i2590-017X-6-1-1-b34","doi-asserted-by":"crossref","unstructured":"Narbutas\n S\u030c,\n \n \n York\n K,\n \n \n Stein\n BD,\n \n et al.\n \n Overview on patient centricity in cancer care.\n\t\t\t\t\tFront Pharmacol.\n\t\t\t\t\t2017;\n\t\t\t\t\t8:\n\t\t\t\t\t698.","DOI":"10.3389\/fphar.2017.00698"},{"key":"2023013016571388300_i2590-017X-6-1-1-b35","doi-asserted-by":"crossref","unstructured":"Rodriguez-Rincon\n D,\n \n \n Leach\n B,\n \n \n d'Angelo\n C,\n \n et al.\n \n Factors affecting access to treatment of early breast cancer: case studies from Brazil, Canada, Italy, Spain and UK: implications for future research, policy and practice. 2019. Accessed Mar 2, 2022.\n \n www.randeurope.org","DOI":"10.7249\/RR3010.4"},{"key":"2023013016571388300_i2590-017X-6-1-1-b36","doi-asserted-by":"crossref","unstructured":"Von Minckwitz\n G,\n \n \n Procter\n M,\n \n \n de Azambuja\n E,\n \n et al.\n \n Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer.\n\t\t\t\t\tN Engl J Med.\n\t\t\t\t\t2017;\n\t\t\t\t\t377:\n\t\t\t\t\t122\u2013\n\t\t\t\t\t131.","DOI":"10.1056\/NEJMoa1703643"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/1\/1\/3184557\/i2590-017x-6-1-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/6\/1\/1\/3184557\/i2590-017x-6-1-1.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:21Z","timestamp":1765475301000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/6\/1\/article-p1.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,13]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12,13]]},"published-print":{"date-parts":[[2023,2,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-22-12","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"type":"electronic","value":"2590-017X"},{"type":"print","value":"2666-2345"}],"subject":[],"published":{"date-parts":[[2022,12,13]]}}}